Search research articles
Contact Us
Filters
Showing results (41-50 of 59) with videos related to
Page
of 6
Sort By:
Journal of Clinical Pharmacology
|
December 5, 2015
Mitigating the Effects of Nonadherence in Clinical Trials
Thomas M Shiovitz, Earle E Bain, David J McCann, et al.
Cellular and Molecular Neurobiology
|
April 26, 2006
Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677
Piotr Popik, Martyna Krawczyk, Krystyna Golembiowska, et al.
Journal of Clinical Pharmacology
|
May 6, 2016
Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose
Philip Krieter, Nora Chiang, Shwe Gyaw, et al.
Science Translational Medicine
|
March 30, 2018
Medication development in opioid addiction: Meaningful clinical end points
Nora D Volkow, Janet Woodcock, Wilson M Compton, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 10, 2009
Preclinical evaluation of the abuse potential of the analgesic bicifadine
Katherine L Nicholson, Robert L Balster, Krystyna Golembiowska, et al.
The International Journal of Neuropsychopharmacology
|
July 26, 2012
Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors
Jack Bergman, Rebecca A Roof, Cheryse A Furman, et al.
BMC Pharmacology
|
June 17, 2008
Pharmacological Properties of DOV 315,090, an ocinaplon metabolite
Dmytro Berezhnoy, Maria C Gravielle, Scott Downing, et al.
Neuropharmacology
|
August 27, 2011
The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf⁺/⁻ heterozygous null mice
Jesse S O Lindholm, Henri Autio, Liisa Vesa, et al.
European Journal of Pharmacology
|
February 21, 2004
Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease
Michael J O'Neill, Tracey K Murray, Katherine Whalley, et al.
Pharmacology, Biochemistry, and Behavior
|
August 14, 2012
Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology
Kaitlin T Warnock, Andrew R S T Yang, Heon S Yi, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 59) with videos related to
Sort By:
Page
of 6
Journal of Clinical Pharmacology
|
December 5, 2015
Mitigating the Effects of Nonadherence in Clinical Trials
Thomas M Shiovitz, Earle E Bain, David J McCann, et al.
Cellular and Molecular Neurobiology
|
April 26, 2006
Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677
Piotr Popik, Martyna Krawczyk, Krystyna Golembiowska, et al.
Journal of Clinical Pharmacology
|
May 6, 2016
Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose
Philip Krieter, Nora Chiang, Shwe Gyaw, et al.
Science Translational Medicine
|
March 30, 2018
Medication development in opioid addiction: Meaningful clinical end points
Nora D Volkow, Janet Woodcock, Wilson M Compton, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 10, 2009
Preclinical evaluation of the abuse potential of the analgesic bicifadine
Katherine L Nicholson, Robert L Balster, Krystyna Golembiowska, et al.
The International Journal of Neuropsychopharmacology
|
July 26, 2012
Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors
Jack Bergman, Rebecca A Roof, Cheryse A Furman, et al.
BMC Pharmacology
|
June 17, 2008
Pharmacological Properties of DOV 315,090, an ocinaplon metabolite
Dmytro Berezhnoy, Maria C Gravielle, Scott Downing, et al.
Neuropharmacology
|
August 27, 2011
The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf⁺/⁻ heterozygous null mice
Jesse S O Lindholm, Henri Autio, Liisa Vesa, et al.
European Journal of Pharmacology
|
February 21, 2004
Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease
Michael J O'Neill, Tracey K Murray, Katherine Whalley, et al.
Pharmacology, Biochemistry, and Behavior
|
August 14, 2012
Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology
Kaitlin T Warnock, Andrew R S T Yang, Heon S Yi, et al.
Page
of 6